Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults

Status:
Recruiting

Trial end date:
2024-03-31

Target enrollment:

Participant gender:

Multicenter, phase III, randomized, blinded, controlled, parallel group with safety extension phase with crossover or continued treatment.

Phase 3

Lyra Therapeutics